Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Efficacy Study of Inhaled AmBisome for Prevention of Aspergillus Colonization in Lung Transplant Recipients

This study has suspended participant recruitment.
(Study has been placed on hold due to unavailability of funding.)
Sponsor:
Information provided by (Responsible Party):
University Health Network, Toronto
ClinicalTrials.gov Identifier:
NCT01254708
First received: November 22, 2010
Last updated: October 18, 2011
Last verified: October 2011

November 22, 2010
October 18, 2011
January 2012
January 2014   (final data collection date for primary outcome measure)
  • Pulmonary Function [ Time Frame: Day 1 to 12 months ] [ Designated as safety issue: Yes ]
    Assess pulmonary function measurements i.e. changes in FEV1 (Forced Expiratory Volume 1), changes in FVC (Forced Vital Capacity) while receiving inhaled liposomal amphotericn B.
  • Symptoms [ Time Frame: Day 1 to 12months ] [ Designated as safety issue: Yes ]
    Assess onset of symptoms including headache, dizziness and fatigue, fever, nausea, vomiting, wheezing, cough, shortness of breath, and taste preservation, while receiving inhaled liposomal amphotericin B
  • Renal or Hepatic dysfunction and Neutropenia [ Time Frame: Day 1 to 12 months ] [ Designated as safety issue: Yes ]
    Assess the development of renal or hepatic dysfunction and neutropenia by measuring serum creatinine liver enzymes and white blood cells
Same as current
Complete list of historical versions of study NCT01254708 on ClinicalTrials.gov Archive Site
Presence of Invasive fungal infection [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Measure the time in months from randomization of study participants to diagnosis of invasive fungal infection (proven or probable). Measure the time in months from randomization to death for study participants.

Assessment of the quality of life at the baseline Month 0, 3, 6, 9 and 12 months based on responses to a questionnaire. These include responses to general questions to rate the level of emotions and the general well being of the study participants. These responses are rated as never, sometimes, often or always experienced.

Same as current
Not Provided
Not Provided
 
Safety and Efficacy Study of Inhaled AmBisome for Prevention of Aspergillus Colonization in Lung Transplant Recipients
A Pilot Study to Determine the Safety and Clinical Efficacy of Once-Weekly Inhaled AmBisome for the Prevention of Aspergillus Colonization in Lung Transplant Recipients

Lung transplant recipients have the highest rate of Invasive Aspergillus (IA)infection among solid organ transplant recipients. The most important risk factor for the development of IA (which is associated with disease and death) is colonization of the organism in the respiratory tract.

Azoles are used to prevent the development of IA. Puffers containing antifungal medication can be used to treat the lungs without the need to worry about the medication interactions & side-effects in the blood. An example of this is the aerosolized amphotericin B. Its use is limited by the patients' tolerating this medication that may cause cough, nausea & contraction of the air pathways.

The lipid preparation is better tolerated and has longer dosing interval than inhaled amphotericin B. The investigators propose a pilot study to determine the long-term safety of inhaled AmBisome administration of drug and generate the preliminary data on the effectiveness of this drug to prevent aspergillus colonization.

In this pilot study, our main aims are:

  1. To determine the safety of once weekly Inhaled AmBisome prophylaxis in preventing the development of Aspergillus colonization in lung transplant recipients at one year of prophylaxis.
  2. To generate the preliminary data on the efficacy of Inhaled AmBisome (Astellas) loading dose (1mg/kg/day for four days) initially followed by q weekly dosage to complete 1 year in lung transplant recipients as compared to no prophylaxis by assessing the rate of fungal colonization/infections between the groups.
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Lung Transplant Recipient
  • Drug: Ambisome ®
    liposomal amphotericin B
  • Drug: Regular standard of care medication
    Drug for this group is at the physician's discretion. Patients in this group receive the standard of care medication currently implemented at the Institution. Example would be voriconazole
  • Active Comparator: Control
    Standard of care group. Medication as prescribed by the primary physician would be used by this group. Such medications might include azoles as voriconazole
    Intervention: Drug: Regular standard of care medication
  • Experimental: liposomal amphotericin B (AmBisome ®)
    Inhaled Liposomal preparation of Amphotericin B.
    Intervention: Drug: Ambisome ®

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Suspended
4
January 2014
January 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Single or double lung transplant recipients who are at least one year out of transplantation.
  2. Age >18yrs of age
  3. Able to understand and complete informed consent.

Exclusion Criteria:

  1. Pregnant woman or woman capable of bearing children, who will not perform urine pregnancy test.
  2. Nursing mothers.
  3. Subjects with hypersensitivity to Amphotericin deoxycholate or liposomal Amphotericin.
  4. Subjects with a past history of bronchospasm associated with aerosol drug use.
  5. Subjects with active bacterial or viral infection as defined by the current use of non-prophylactic antibiotic anti-viral medications.
  6. Subjects treated with cytolytic medications (Campath /Thymoglobulin) within the last month.
  7. Subjects with an FEV1< 30% Predicted or FVC% <30%.
  8. Subjects requiring supplemental oxygen.
  9. Receipt of Inhaled or IV Amphotericin B within last 30 days.
  10. Subjects with known fungal infection as per MSG Criteria on therapy with antifungal drugs or diagnosed on the day of bronchoscopy.
  11. Current use of azoles active against molds (Voriconazole, itraconazole, posaconazole) for the prophylaxis.
  12. Serum creatinine > 150 mmol/L on the day of clinic visit.
  13. Liver enzymes ALT/ AST/ Alkphos greater than two times upper limit of normal.
  14. Concurrent intravenous aminoglycoside use.
  15. Subjects with fever > 38.2°C.
  16. Subjects on mechanical ventilation.
  17. Expected survival less than 6 months.
  18. Re-transplants and heart/lung transplant patients.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT01254708
AGM201000428
Not Provided
University Health Network, Toronto
University Health Network, Toronto
Not Provided
Principal Investigator: Shahid Husain, M.D M.Sc University Health Network, Toronto
University Health Network, Toronto
October 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP